ArticleAnnals of medicine and surgery (2012)2025
Reactivation of cereberal tuberculosis post-adalimumab therapy for rheumatoid arthritis: a case report.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- High baseline neutrophil-to-lymphocyte ratio is associated with better adalimumab response in patients with rheumatoid arthritis.The Journal of international medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and importance: Patients with rheumatoid arthritis who are treated with adalimumab have an increased risk of developing latent infections. The lethal risk of TB encephalitis as a potential manifestation after treatment with adalimumab should not be overlooked despite its rarity. Case presentation: We report a case of a 19-year-old Middle Eastern female who developed cerebral tuberculosis after receiving adalimumab therapy for rheumatoid arthritis. The patient was systemically well. Her medical history included pneumonia, PCOs (polycystic ovary syndrome), and Clinical disscusion: Rheumatoid arthritis patients who are treated with DMARDs are at risk of developing opportunistic infections. While most opportunistic infections are well understood and have clear symptoms, the rare occurrence of encephalitis should not be dismissed. Conclusion: Although rare, TB encephalitis should be considered in patients developing neurological symptoms after treatment with Adalimumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.